Western Securities: Maintains Buy rating on Highvision Medical (02407.HK) with an increase in the income from its self-owned products in H1 25.

According to the China Fortune Finance app, West Securities released a research report stating that it is expected that from 2025 to 2027, the revenue of Highv Medical (02407.HK) will be 1.564 billion, 1.715 billion, and 1.875 billion yuan, with year-on-year growth of 9.48%, 9.67%, and 9.33%; net profit attributable to shareholders will be 0.135 billion, 0.18 billion, and 0.214 billion yuan, with year-on-year growth of 45.85%, 33.71%, and 18.99%; maintaining a "hold" rating. In the first half of 2025, the company achieved total operating income of 653 million yuan, a year-on-year increase of 1.72%; net profit attributable to shareholders was 38 million yuan, a year-on-year increase of 33.37%; gross profit margin increased by 1.86 percentage points.